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c-Myc is known to promote glutamine usage by
upregulating glutaminase (GLS), which converts
glutamine to glutamate that is catabolized in the
TCA cycle. Here we report that in a number of
human and murine cells and cancers, Myc induces
elevated expression of glutamate-ammonia ligase
(GLUL), also termed glutamine synthetase (GS),
which catalyzes the de novo synthesis of glutamine
from glutamate and ammonia. This is through upre-
gulation of a Myc transcriptional target thymine DNA
glycosylase (TDG), which promotes active demethy-
lation of the GS promoter and its increased expres-
sion. Elevated expression of GS promotes cell
survival under glutamine limitation, while silencing
of GS decreases cell proliferation and xenograft
tumor growth. Upon GS overexpression, increased
glutamine enhances nucleotide synthesis and amino
acid transport. These results demonstrate an unex-
pected role of Myc in inducing glutamine synthesis
and suggest a molecular connection between DNA
demethylation and glutamine metabolism in Myc-
driven cancers.
INTRODUCTION
Cancer cells rewire their metabolic programs including abnormal
glutamine metabolism to benefit their growth, proliferation, and
survival (DeBerardinis et al., 2008). Some cancer cell lines
display increased glutamine uptake and catabolism to fuel
the tricyclic acid (TCA) cycle that render cells addicted to gluta-
mine. Nonetheless, in addition to being a nutrient substrate,1068 Cell Metabolism 22, 1068–1077, December 1, 2015 ª2015 Elseglutamine is involved in other biological processes, including
serving as the obligate nitrogen donor for the synthesis of nucle-
otides and nonessential amino acids, as an exchanger for the
import of essential amino acids, and as a means to detoxifying
intracellular ammonia and glutamate (Dang, 2012; DeBerardinis
and Cheng, 2010; Hensley et al., 2013; Wise and Thompson,
2010)
While the metabolic changes in cancer cells can be promoted
by a passive cell adaptation to environmental conditions such as
hypoxia and redox stress, they are often actively regulated by
genetic alterations such as activation of oncoproteins and loss
of tumor suppressors (DeBerardinis et al., 2008; Kroemer and
Pouyssegur, 2008; Vander Heiden et al., 2009). Two proto-onco-
proteins, Akt and c-Myc (hereafter referred to asMyc), have been
intensively studied for their functions in regulating cell meta-
bolism. Both Akt and Myc can promote aerobic glycolysis, also
termed the Warburg effect. With regard to glutamine meta-
bolism, while studies to date suggest that Akt minimally impacts
glutamine metabolism (Fan et al., 2013), oncogenic Myc has
been shown to promote glutamine uptake by directly transacti-
vating the expression of glutamine transporters SLC1A5 and
SLC7A5/SLC3A2 (Nicklin et al., 2009), and to promote glutami-
nolysis by increasing the expression of glutaminase (GLS) via
transcriptional suppression of the GLS repressor micro RNAs
(miR)-23a/b (Gao et al., 2009). In a previous study, we estab-
lished an isogenic dual-regulatable FL5.12 pre-B cell line in
which myrAkt is expressed under the control of doxycycline
(DOX), and Myc, fused to the hormone-binding domain of the
human estrogen receptor (ER), is activated by 4-hydroxytamox-
ifen (4-OHT) (Fan et al., 2010). Using this system, we compare
the effects of Akt and Myc on gene expression using the Affyme-
trix DNA array analysis. To our surprise, we found that Myc but
not Akt can upregulate the expression of glutamine synthetase
(GS), the enzyme that catalyzes the synthesis of glutamine
from glutamate and ammonia, which is the reverse reaction of
glutaminolysis that is catalyzed by GLS.vier Inc.
RESULTS
Myc Upregulates GS Expression and Activity
In the FL5.12 Akt/Myc (AM) clones that we previously estab-
lished where myrAkt and Myc can be induced individually or
simultaneously in an isogenic background (Fan et al., 2010),
GS expression was found to increase uponMyc but not Akt acti-
vation using an Affymetrix mouse cDNA array (Figure 1A). This in-
duction of GS expression was confirmed in two individual clones
(AM10 and AM32) at both the transcription (Figure 1B) and pro-
tein levels (Figure 1C), which was accompanied by an increased
GS enzymatic activity (Figure 1D). Under a physiological setting,
introduction of Myc into the Pdx1-Cre; LSL-KRasG12D model
(Hingorani et al., 2003) by breeding it to the Rosa26-LSL-Myc
mice (Murphy et al., 2008) led to a massive increase of GS
expression in the pancreatic ductal neoplasia compared with
the age-matched control KRasG12D mice (Figure 1E). In the
lung tumor cells isolated from the LSL-KRasG12D; tp53flox/flox
mice (Jackson et al., 2001), induction of Myc using the MycER
system also led to elevated GS mRNA level (Figure 1F). In the
immortalized yet nontransformed human mammary epithelial
cell line MCF10A, expression of Myc (Figure 1G), which stimu-
lated cell proliferation (Figure 1H), also led to elevated GS
expression at both protein (Figure 1G) and transcript levels (Fig-
ure 1I), accompanied by increased enzymatic activity (Figure 1J).
It is interesting to note that GLS protein level did not increase
in this system (Figure 1G). Using the Cancer Genome Atlas
(TCGA) data of human T-lymphoma with Myc amplification, a
strong correlation between Myc amplification and GS expres-
sion was observed (Figure 1K). Conversely, in a number of hu-
man cancer cell lines, silencing of endogenous Myc led to
decreased GS expression yet variable changes in the GLS level
(Figure 1L). These data indicate that Myc upregulation can pro-
mote GS expression in numerous mouse and human cell lines
and cancers.
Myc Directly Upregulates TDG that Leads to GS
Expression via Promoter Demethylation
We next studied how Myc induces GS expression. As Myc
amplification is amajor oncogenic event in human breast cancer,
we focused on human breast epithelial cell lines for the following
studies. Five out of the six breast cancer cell lines that we
examined showed strong GS expression, excluding Hs578T
cells (Figure 2A). Therefore, we utilized Hs578T cells to study
the effect of GS upregulation in cancerous cells. We also chose
to use MCF10A cells which have low levels of GS expression
(Figure 1G) to study GS regulation upon Myc activation in non-
transformed cells. Myc is a helix-loop-helix leucine zipper family
transcriptional regulator that dimerizes with Max family proteins
to bind the CAC(G/A)TG (E box) sequence and directly activates
transcription of its target genes. However, analysis of the puta-
tive GS promoter regions using the Genomatix Genome Analyzer
(http://www.genomatix.de) and the SABiosciences Transcrip-
tion Factor Search Portal (http://www.sabiosciences.com)
showed no canonical Myc binding sites in human, mouse, or
rat GS promoters, consistent with previous analysis of the GS
promoter (Kung et al., 2011). Interestingly, we noticed G/C rich
regions spanning the transcriptional starting site in the GS
gene, which was predicted to be a CpG island (Figure 2B). ThisCell Metabsuggested a possible mechanism of transcriptional regulation
by DNA methylation of the GS promoter. Indeed, treatment
with 5-azacytidine, a DNAmethyltransferase inhibitor, enhanced
GS expression in both MCF10A and Hs578T cells (Figure 2C).
Bisulfite sequencing showed that the GS promoter was indeed
methylated and thatMyc expression led to its decreasedmethyl-
ation (Figure 2D). To determine how Myc affects GS promoter
methylation, we examined the expression of the major DNA
methyltransferases and demethylases upon Myc expression.
While Myc did not significantly change the expression level of
DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, or
that of the DNA demethylases TET1, TET2, and MBD4 (see Fig-
ure S1A available online), it markedly increased the expression
of TET3 (Figure S1A) and TDG (Figure 2E). This suggests that
Myc can induce ‘‘active demethylation’’ by upregulating TET3,
which oxidizes 5-methylcytosine (5mC), and TDG, which then
removes the oxidized products via excision repair (He et al.,
2011; Ito et al., 2011). Supporting the active demethylation
theory, increased DNA demethylase activity was observed in
Myc-expressing cells (Figure 2F). Gemcitabine, a pharmacolog-
ical inhibitor of DNA demethylation, suppressed Myc-induced
GS expression in both MCF10A-Myc (Figure 2G) and in
FL5.12-AM32 cells (Figure S1B).
We further characterized how Myc induces TET3 and TDG
expression. Interestingly, two recent independent genome-wide
chromatin immunoprecipitation-sequencing (ChIP-Seq) analyses
suggested that Myc can directly bind to the promoter of TDG but
not of TET3 (Perna et al., 2012; Walz et al., 2014). Promoter anal-
ysis identified two putative E-boxes in TDG promoter. ChIP-PCR
analysis using the Myc antibody and two specific sequences
containing the E-boxes revealed that Myc is recruited to the
TDGpromoter (Figure 2H).We then generated luciferase reporter
constructs driven by wild-type TDG promoter or promoters
mutated at E-box consensus sites. While the wild-type promoter
drove a significantly higher luciferase activity in Myc-expressing
cells, both single E-box mutants and the double mutant lost the
Myc-mediated inducibility (Figure 2I). Using the FL5.12-MycER
cells and MCF10A-MycER cells where Myc can be acutely
induced, a rapid induction of GS and TDGwas observed as early
as 4 and 8 hr, respectively, upon Myc activation (Figures 2J and
S1C), which correlated with decreased GS promoter methylation
(Figures S1D and S1E) and is consistent with the active demethy-
lation mechanism which is replication independent. Lastly, TDG
silencing in Myc-expressing MCF10A cells abrogated Myc-
induced GS expression (Figure 2K). Therefore, we identified a
previously undescribed mechanism whereby Myc activates GS
expression via the demethylation of its promoter.
Myc-Induced GS Promotes Glutamine Metabolism
We then studied the effect of GS in cancer cells. GS was ectopi-
cally expressed in Hs578T cells (Figure 3A), and cells were incu-
bated with 15N-labeled ammonia (NH4Cl) and subjected to gas
chromatography-mass spectrometry (GC-MS) analysis. In vector
control cells 30% of the intracellular glutamine was m+1 (15N1)
labeled,which is producedby the condensation ofm+0glutamate
andNH4Cl. TheexpressionofGSsignificantly increased
15N incor-
poration into glutamine with over 40% of the glutamine m+1
labeled (Figure 3B), demonstrating that GS promotes glutamine
synthesis.olism 22, 1068–1077, December 1, 2015 ª2015 Elsevier Inc. 1069
Figure 1. Myc Upregulates GS Expression
(A–D) FL5.12 parental cells and the AM clones (AM10 and AM32) were cultured in the control medium, with Dox to activate Akt, or 4-OHT to activate Myc, or both,
for 36 hr. Fold change of GS transcript bymouse cDNA array is shown (A). Relative GS transcript level determined by qRT-PCR is shown as themean plus SEM of
a representative experiment performed in triplicates (B). Cell lysates were analyzed by immunoblotting (C). GS activity was determined and is shown as the mean
plus SEM of at least five independent experiments (D).
(E) Pancreata from 2-month-old Pdx1-Cre; LSL-KRasG12D (n = 4) and age-matched Pdx1-Cre; LSL-KRasG12D; R26-LSL-MYC (n = 4) mice were stained for GS
by IHC. I, islets; N, normal tissue; T, tumors. Note that normal islet stains positive for GS.
(F) Murine lung tumor cells derived from viral-Cre induced LSL-KRasG12D; p53fl/fl mice were infected with pBabe-MycERT2 and treated for 24 hr with ethanol
vehicle or 100 nM 4-OHT. mRNA was subjected to Illumina sequencing. GS mRNA levels are expressed as number of sequencing reads (mean plus SD [n = 4]).
(G–J) MCF10A cells were stably transfected with vector or pBabe-c-Myc. Cells were subjected to immunoblotting (G). Cell growth was measured and shown as
the mean plus SD of a representative experiment of three independent experiments performed in triplicates (H). GS transcript level analyzed by qRT-PCR is
shown as the mean plus SEM of three independent experiments performed in duplicates (I). GS activity is shown as the mean plus SEM of three independent
experiments (J).
(K) Differential expression levels of GS in Myc-high and Myc-low groups in T cell lymphoma. Shown are box plots of expression levels of GS. The Myc high and
Myc low groups were defined by Myc expression above or below the median level.
(L) Indicated cell lines were stably infected with indicated shRNAs and subjected to immunoblotting.
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Figure 2. Myc Upregulates GS Expression via TDG-Mediated Demethylation of GS Promoter
(A) Indicated breast cancer cell lines were probed for GS expression.
(B) Schematic representation of the CpG distribution in the 50-regulatory region of theGLUL gene from the CpG Island Searcher (http://cpgislands.usc.edu/). The
CpG sites are represented by vertical tick marks, and the beginning of exon 1 is depicted as ‘‘+1.’’
(C) MCF10A cells and Hs578T cells were treatedwith 20 mM5-azacytidine (5-Aza). GS transcript level determined via qRT-PCR is shown as themean plus SEMof
a representative experiment performed in triplicates.
(D) Single cell clones of vector control andMyc-expressing MCF10A cells were established by limited dilution. The GS promoter was PCR amplified in five clones
of each cell type, and analyzed by bisulfate sequencing. The schematics of the sequencing results and the human GS promoter with the numbered CpGs are
shown. Open and filled circles indicate unmethylated and methylated cytosines, respectively.
(legend continued on next page)
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Myc is known to promote glutaminolysis which leads to
increased anaplerosis at the aKG step of the TCA cycle (DeBer-
ardinis et al., 2007; Wise et al., 2008). Hence GS-promoted
glutamine synthesis might be expected to consume TCA cycle
intermediates, of which a major source is glucose. Therefore,
13C-glucose was traced in GS-expressing Hs578T cells in the
absence of glutamine. Consistent with the 15N-NH4Cl labeling,
tracing of the 13C-labeled glucose showed increased glutamine
in GS-expressing Hs578T cells (Figure 3C), accompanied by a
reduced relative abundance of glutamate (Figure 3D) and aKG
(Figure 3E). We did not observe significant changes in 13C incor-
poration into pyruvate and lactate, two of the glycolytic metabo-
lites most proximal to the TCA cycle (Figure 3F), nor did we
observe a significant difference in the TCA cycle intermediate
citrate (Figure 3F). Moreover, the abundance of succinate, fuma-
rate, and malate were significantly reduced (Figure 3F). These
data suggest that enforced expression of GS may promote cat-
aplerotic efflux of the TCA cycle from the point of aKG.
Based on these data, we sought to determine the fate of newly
synthesized glutamine in the context of GS or Myc overexpres-
sion. Aside from the anapleurotic role of glutamine in contrib-
uting carbons to the TCA cycle, glutamine plays a major role in
a variety of cellular anabolic processes predominately via the
donation of the terminal nitrogen group which can be assayed
via 15N-NH4Cl labeling. To directly determine the fate of gluta-
mine, we utilized the 15N-NH4Cl labeling followed by methanol
extraction of metabolites then tracing via liquid chromatog-
raphy-mass spectrometry (LC-MS). Consistent with the GC-MS
data (Figure 3B), LC-MS also revealed significant incorporation
of 15N into glutamine accompanied by increased asparagine,
the recipient of the terminal 15N-amine group donated by gluta-
mine (Figure 3G). Interestingly, labeling patterns revealed that
while the incorporation of 15N into glutathione, which is synthe-
sized from glutamate, was reduced, the 15N incorporation into ri-
bonucleosides and monophosphate nucleotides was markedly
increased in GS-expressing cells (Figure 3G).
Next, we studied the metabolic effect of Myc expression using
MCF10A cells. Importantly, similar to the GS-overexpressing
Hs578T cells (Figure 3B), an increase in the fraction of m+1
(15N1) glutamine was observed in Myc-expressing MCF10A cells
by GC-MS using the 15N-NH4Cl labeling (Figure 3H). As GS pro-
moted nucleotide synthesis (Figure 3G) and Myc stimulated
MCF10A cell proliferation (Figure 1J), we examined whether
GS plays a role in Myc-induced nucleotide synthesis, which
would correlate with increased DNA synthesis and cell prolifera-(E) TDG transcript level in Myc-expressing MCF10A cells was analyzed by qRT
performed in triplicates.
(F) DNA demethylase activity was determined in Myc-expressing MCF10A cells
(G) Vector control (v) and Myc-expressing (m) MCF10A cells were treated with g
(H) The level of Myc binding to the TDG promoter in Myc-expressing MCF10A cel
specific regions within the promoter (PCR#1 and PCR#2). Fold enhancement rep
(I) MCF10A cells were transfected with the luciferase reporters driven by the pGL3
the two E-boxes mutated individually or simultaneously, together with a renilla lu
and standardized based on renilla luciferase activity and normalized to that of th
formed in triplicates).
(J) FL5.12-AM32 cells were cultured in 4-OHT to induce Myc activation. Transcrip
SEM from two independent experiments performed in triplicates.
(K) MCF10A cells were stably infected with indicated shRNAs. TDG transcript lev
triplicates).
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cells (Figure 3I), and cells were subjected to 15N-NH4Cl labeling
followed by LC-MS. Myc activation led to increased 15N-gluta-
mine and 15N-asparagine, which was markedly reduced upon
GS silencing (Figure 3J). The 15N incorporation into glutathione
was not drastically affected upon GS silencing, suggesting GS-
independent regulation mechanisms for glutathione in Myc-
active cells (Figure 3J). Importantly, in Myc-overexpressing cells,
although they did not show drastically increased steady-state
levels of methanol-soluble free ribonucleosides, likely due to
the faster incorporation of nucleotides into DNA or RNA strands
as indicated by faster proliferation of the Myc cells, GS silencing
led to a marked decrease of the steady-state level of 15N incor-
poration into ribonucleosides (Figure 3J). Together, these results
strongly indicate that GS promotes glutamine production which
can be used for anabolic processes such as synthesis of aspar-
agine and nucleotides in Myc active cells.
GS Promotes Amino Acid Transport, Cell Survival, and
Oncogenesis
To assay another downstream function of this glutamine anabolic
program, we tested the possibility of glutamine acting as an
exchange factor in the bidirectional transport of leucine (Nicklin
et al., 2009). Overexpression of GS alone was sufficient to
increase leucine uptake by 20%, in a System L-dependent
manner as the uptake was abrogated by the System L inhibitor
BCH (Figure 4A, left and right panels). The importance of intracel-
lular amino acids for system L-mediated leucine uptake in both
cell lines was also demonstrated by the inhibition of leucine up-
take when cells were incubated in amino acid-depleted media
(Figure 4A, KRB). Additionally, high level of GS provided a sus-
tained ability to uptake leucine even in the absence of extracel-
lular glutamine (Figure 4A), in agreement with GS contributing
to increased intracellular levels of glutamine that act as an efflux
substrate for the uptake of leucine (Krokowski et al., 2013; Nicklin
et al., 2009). Consistent with the increased leucine uptake and
glutamine efflux, increased levels of extracellular glutamine was
detected in GS-expressing cells (Figure 4B).
We then determined the biological consequences of GS
expression. In Hs578T cells, overexpression of GS enhanced
cell viability upon glutamine deprivation (Figure 4C). Conversely,
silencing GS in Myc-expressing MCF10A cells led to decreased
cell proliferation in complete medium (Figure 4D) and sensitized
cells to glutamine deprivation (Figure 4E). The generality of this
phenomenon was further illustrated by silencing GS with two-PCR and is shown as the mean plus SEM of five independent experiments
and shown as the mean plus SEM of four independent experiments.
emcitabine for 24 hr and subjected to immunoblotting.
ls was analyzed by ChIP assay using the Myc antibody followed by PCR of two
resents the abundance of enriched DNA fragments over an IgG control.
control vector, the wild-type TDG promoter, or the TDG promoter mutants with
ciferase construct. Luciferase activity in cell lysates was quantified after 24 hr,
e pGL3-transfected cells (mean plus SD of a representative experiment per-
t levels of GS and TDG determined by qRT-PCR are shown as the mean plus
el was analyzed by qRT-PCR (mean plus SEM of an experiment performed in
vier Inc.
Figure 3. GS Leads to Increased Cataplerotic Flux toward Glutamine Synthesis and Promotes Nucleotide Synthesis
(A) Hs578T cells were stably transfected with vector control or GS.
(B) Cells were labeled with 15N-NH4Cl for 6 hr in glutamine-deficient media and nitrogen incorporation into glutamine was determined by GC-MS. Fractions of
glutamine isotopologues were normalized for stable isotope natural abundances.
(C–F) Metabolic tracing analysis of the GS-expressing Hs578T cells. Cells were cultured in glutamine-free medium for 16 hr before labeling with 12.5 mM
13C-glucose for 6 hr in glutamine-freemedium. Relative abundance of 12C and 13C in eachmetabolite pool wasmeasured by GC-MS, and is expressed relative to
the internal standard and protein content in each sample normalized to the value of 12C fraction in vector control cells (C, glutamine; D, glutamate; E, a-KG; F,
other indicated metabolites). All data represent total labeling, i.e., all isotopologues. Shown is the mean plus SD from three (in some cases two) samples.
(G) Cells were labeled for 16 hr with 15N-NH4Cl in glutamine-replete (2 mM) medium and subjected to LC-MS. Percent of each
15N labeled molecule is shown. All
data represent total labeling (mean plus SD from three individual samples).
(legend continued on next page)
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independent shRNAs in MCF10A-Myc and the more aggres-
sive breast cancer cell lines MDA-MB-231 and MDA-MB-468
(Figure 4F), which led to decreased proliferation (Figure 4G).
Silencing of GS did not have an obvious effect on the non-trans-
formed MCF10A parental cells (Figures 4F and 4G). GS silencing
also led to spontaneous cell death in MDA-MB-231 cells (Fig-
ure 4H). The pro-survival role of GS was further demonstrated
using the GS inhibitor MSO that enhanced cell sensitivity to
glutamine deprivation in Myc-expressing cells (Figure 4I). Inter-
estingly, unlike MSO, BPTES, the inhibitor of GLS, did not confer
sensitivity to glutamine deprivation but rather suppressed cell
death in the MCF10A-Myc cells (Figures 4J and 4K), consistent
with an anabolism-promoting function of glutamine. Further-
more, to test the effect of GS suppression in vivo, we introduced
a Tet-inducible GS shRNA inMDA-MB-468 cells that have a high
level of endogenous GS. Addition of doxycycline led to a pro-
gressive loss of GS (Figure 4L) as well as decreased cell growth
(Figure 4M) and xenograft tumor growth (Figure 4N). These data
indicate that GS promotes cell proliferation and survival, and
may be a viable therapeutic target in Myc-driven cancers.
DISCUSSION
Here we report that Myc upregulates expression of GS, the
enzyme that catalyzes the formation of glutamine from glutamate
and ammonia. ThisMyc-inducedGSexpression promotes gluta-
mine anabolism and is associated with cell proliferation, survival,
and xenograft tumor growth, suggesting an important role of
GS in Myc-driven oncogenesis. In addition to being a nutrient
substrate, glutamine is involved in many biological processes,
including serving as the obligate nitrogen donor formultiple steps
in both purine and pyrimidine synthesis and contributing to the
production of nonessential amino acids (DeBerardinis and
Cheng, 2010; Wise and Thompson, 2010). Indeed, our data indi-
cate that several fates elucidated for newly synthesized gluta-
mine, namely nucleotide and asparagine synthesis as well as
amino acid transport (Figures 3F and 4A), fit into the anabolism-
promoting role of glutamine.
The connection between Myc and numerous essential cellular
processes (macromolecule biosynthesis, ribosome biogenesis,
and DNA replication) has previously been established and offers
an explanation for the enhanced glutamine anabolism we report.
GS-driven glutamine synthesis is the only known reaction for
endogenous glutamine production. In mammals, nearly 90% of
glutamine production originates from endogenous sources (Biolo
et al., 2005; Kuhn et al., 1999). While muscle tissue accounts for
the majority of synthesized glutamine that can be released into
the circulating system and taken up by other tissues and tumors,
many tissues and cell types have the ability to upregulate GS and
glutamine synthesis upon glutamine shortage (He et al., 2010;
Newsholmeetal., 2003). In cellswithMycamplification, increased
biosyntheticprocessesmay increase thedemand forglutamine to
serve as a basis for many anabolic processes. This is supported(H) MCF10A cells were labeled with 15N-NH4Cl for 6 hr in glutamine-freemedium a
of glutamine was normalized for stable isotope natural abundances.
(I and J) MCF10A cells were stably infected with indicated shRNAs. (I) Success
glutamine-replete (2mM)medium and subjected to LC-MS. Percent of each 15N la
representative of three independent experiments performed in triplicate).
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to be elevated in human glioblastoma (Maher et al., 2012). There-
fore, oncogenic Myc may hijack the glutamine synthesis system
to ensure glutamine supply for autonomous need or perhaps in
a symbiotic fashion that benefits tumor tissue heterogeneity and
microenvironment, especially under the condition of glutamine
shortage such as in poorly vascularized tumors.
While our findings are seemingly paradoxical to Myc’s role in
promoting glutaminolysis to fuel the TCA cycle, it is not entirely
surprising. Indeed, recent reports highlighted glucose oxidation
as a predominant fuel source in patient samples and human or-
thotopic tumor models which show glucose as a means of ana-
plerosis and accumulation of glutamine in tumors (Maher et al.,
2012; Marin-Valencia et al., 2012). Myc may preferentially acti-
vate either glutaminolysis or glutamine synthesis in a context-
dependent manner. This notion is supported by the observations
that Myc often does not lead to simultaneous upregulation of
GLS and GS (Yuneva et al., 2012), and that a mutual suppressive
mechanism may exist between GS and GLS in various breast
cancer subtypes (Kung et al., 2011). In addition, even within a
single cell, the two reactions may be tightly regulated as they
occur at different subcellular compartments: glutaminolysis
predominantly in mitochondria and glutamine synthesis in the
cytosol (Svenneby and Torgner, 1987).
We also show that Myc-induced GS expression is mediated
by a mechanism that involves active promoter demethylation.
DNA methylation has been regarded as a critical factor in onco-
genesis yet its precise role and regulation remain largely elusive.
Nevertheless, global hypomethylation has also been prevalently
detected and recognized as a cause for cancer, although the
regulation of specific genes is yet to be illustrated (Kulis and Es-
teller, 2010). Our current data provide an example showing that
Myc can induce DNA demethylation and alter cell metabolism.
This is consistent with the evidence that active DNA demethyla-
tion plays an important role in the development of germ cells and
pluripotent stem cells (Wu and Zhang, 2014), which share many
common signaling pathways and metabolic alterations with
Myc-driven oncogenesis (Goding et al., 2014).
EXPERIMENTAL PROCEDURES
Cell Death Assay
Propidium iodide (PI) was added to each sample at 1 mg/ml. Cell viability was
measured by plasmamembrane permeability indicated by PI exclusion using a
flow cytometer (FACSCalibur, BD Biosciences).
Cell Growth Assay
Cell growth rate was measured by crystal violet staining. Briefly, cells were
fixed with 4% PFA then stained with 0.1% crystal violet. After washing, crystal
violet was extracted with 10% acetic acid, and absorbance was measured at
590 nm.
Amino Acid Transport Assays
Amino acid uptake was performed as previously described (Krokowski et al.,
2013).nd nitrogen incorporation into glutamine was determined by GC-MS. Total pool
ful GS silencing is shown. (J) Cells were labeled for 16 hr with 15N-NH4Cl in
beledmolecule is shown. All data represent total labeling (mean plus SD from a
vier Inc.
Figure 4. GS Promotes Amino Acid Uptake and Tumorigenesis
(A) Hs578T cells were tested for leucine uptake at basal conditions, under amino acid withdrawal (KRB), and under glutamine deprivation alone for 5 hr. System
L-dependent uptake of leucine was assayed in EBSS without sodium and confirmed by the use of the System L inhibitor BCH.
(B) Extracellular glutamine levels in media from Hs578T cells. Concentration was normalized to protein concentration and displayed as a fold change from vector
cells (mean plus SD of two experiments performed in triplicates).
(C) Hs578T cells were cultured in glutamine-free medium. Cell viability is shown as the mean plus SD of three independent experiments.
(D and E) Myc-expressingMCF10A cells with shNTC or shGSwere cultured in complete (D) or glutamine-freemedium (E). Cell growth (D) and cell viability (E) were
measured.
(F and G) Indicated cell lines were stably infected with two independent GS shRNAs. Successful silencing is shown (F). Cells growth in complete medium was
measured (G).
(legend continued on next page)
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Quantitative RT-PCR
Total RNA was isolated with RNeasy kit (QIAGEN). Reverse transcription
was carried out with 2 mg of total RNA using the SuperscriptIII First Strand
Synthesis system (Invitrogen). The synthesized cDNA was used for real-time
quantitative PCR (qPCR) with the PerfeCTa SYBR Green Super mix (Quanta
Bioscience 95055) on the StepOnePlus (Applied Biosystems).
Stable Isotope-Based Metabolite Tracing
13C-glucose and 15N-NH4Cl labeling coupledwith GC-MSwas performed at the
metabolomics cores atMcGill University andStonyBrookUniversity. 15N-NH4Cl
labelingcoupledwithLC-MSwasperformedat theDepartmentofChemistryand
Lewis-Sigler Institute for Integrative Genomics at Princeton University.
Animals
Female athymic nude mice, 6 to 8 weeks old, were purchased from Charles
River Laboratories. Mice were housed and monitored at the Division of Labo-
ratory Animal Resources at Stony Brook University. All experimental proce-
dures and protocols were approved by the Stony Brook University Institutional
Animal Care and Use Committee (IACUC).
Statistical Analyses
The longitudinal data analyses were performed to assess the growth curves.
The ANOVA procedures were used to evaluate differences among multiple
groups with the Dunnett or Newman-Keuls test. The independent two-sample
and one-sample t tests were used to make comparisons between two groups
and to evaluate whether fold changes are different from one, respectively. The
analyses were mainly carried out using PROC MIXED, PROC FREQ, PROC
MEANS, and PROC TTEST in the SAS 9.4 (SAS institute, Cary, NC). Some
initial analyses were also carried out with GraphPad Prism 5 for Windows.
Different levels of statistical significance are indicated as follows: n.s., nonsig-
nificant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
More detailed experimental procedures can be found in Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and one figure and can be found with this article at http://dx.doi.org/10.
1016/j.cmet.2015.09.025.
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